To include your compound in the COVID-19 Resource Center, submit it here.

Shin Nippon Biomedical Laboratories, G2B deal

Shin Nippon granted G2B an option for non-exclusive rights to its

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE